This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
Study Type
OBSERVATIONAL
Enrollment
48
No treatment (intervention) was administered.
Unnamed facility
Bergen, Norway
Unnamed facility
Wakefield, United Kingdom
Dose of Botulinum Toxin Used to Treat Cervical Dystonia
The average dose of botulinum toxin received per patient per year was calculated.
Time frame: 2 Years
Dose of Botulinum Toxin Used to Treat Blepharospasm
The average dose of botulinum toxin received per patient per year was calculated.
Time frame: 2 Years
Number of Participants With Adverse Events
An Adverse Event was any unfavorable and unintended sign, symptom, or disease documented in the medical chart that occurred after treatment with botulinum toxin, or pre-existing conditions that worsened during the retrospective period.
Time frame: 2 Years
Botulinum Toxin Inter-injection Interval
Injection-interval was the time in weeks between injections of botulinum toxin.
Time frame: 2 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.